Literature DB >> 9275024

DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.

P De Feudis1, D Debernardis, P Beccaglia, M Valenti, E Graniela Siré, D Arzani, S Stanzione, S Parodi, M D'Incalci, P Russo, M Broggini.   

Abstract

Nine human ovarian cancer cell lines that express wild-type (wt) or mutated (mut) p53 were used to evaluate the cytotoxicity induced by cisplatin (DDP). The concentrations inhibiting the growth by 50% (IC50) were calculated for each cell line, and no differences were found between cells expressing wt p53 and mut p53. Using, for each cell line, the DDP IC50, we found that these concentrations were able to induce an increase in p53 levels in all four wt-p53-expressing cell lines and in one out of five mut-p53-expressing cell lines. WAF1 and GADD45 mRNAs were also increased by DDP treatment, independently of the presence of a wt p53. Bax levels were only marginally affected by DDP, and this was observed in both wt-p53- and mut-p53-expressing cells. DDP-induced apoptosis was evident 72 h after treatment, and the percentage of cells undergoing apoptosis was slightly higher for wt-p53-expressing cells. However, at doses near the IC50, the percentage of apoptotic cells was less than 20% in all the cell lines investigated. We conclude that the presence of wt p53 is not a determinant for the cytotoxicity induced by DDP in human ovarian cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9275024      PMCID: PMC2227984          DOI: 10.1038/bjc.1997.412

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.

Authors:  D Debernardis; E G Siré; P De Feudis; F Vikhanskaya; M Valenti; P Russo; S Parodi; M D'Incalci; M Broggini
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

Review 3.  Cancer of the ovary.

Authors:  S A Cannistra
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

4.  Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53.

Authors:  F Vikhanskaya; E Erba; M D'Incalci; M Broggini
Journal:  Nucleic Acids Res       Date:  1994-03-25       Impact factor: 16.971

5.  Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II).

Authors:  A Eastman
Journal:  Biochemistry       Date:  1983-08-02       Impact factor: 3.162

6.  Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.

Authors:  R Brown; C Clugston; P Burns; A Edlin; P Vasey; B Vojtĕsek; S B Kaye
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

7.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

Review 8.  Features of apoptotic cells measured by flow cytometry.

Authors:  Z Darzynkiewicz; S Bruno; G Del Bino; W Gorczyca; M A Hotz; P Lassota; F Traganos
Journal:  Cytometry       Date:  1992

Review 9.  Nucleotide excision repair. II: From yeast to mammals.

Authors:  J H Hoeijmakers
Journal:  Trends Genet       Date:  1993-06       Impact factor: 11.639

10.  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.

Authors:  X W Wang; K Forrester; H Yeh; M A Feitelson; J R Gu; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  20 in total

1.  Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.

Authors:  P De Feudis; S Vignati; C Rossi; T Mincioni; R Giavazzi; M D'Incalci; M Broggini
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Kaustubh Bhinge; Vineet Gupta; Xin Gu; S Michal Jazwinski
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

Review 3.  Gadd45 proteins: relevance to aging, longevity and age-related pathologies.

Authors:  Alexey A Moskalev; Zeljka Smit-McBride; Mikhail V Shaposhnikov; Ekaterina N Plyusnina; Alex Zhavoronkov; Arie Budovsky; Robi Tacutu; Vadim E Fraifeld
Journal:  Ageing Res Rev       Date:  2011-10-05       Impact factor: 10.895

4.  Cisplatinum and taxol induce different patterns of p53 phosphorylation.

Authors:  G Damia; L Filiberti; F Vikhanskaya; L Carrassa; Y Taya; M D'incalci; M Broggini
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

5.  Mechanisms of resistance to alkylating agents.

Authors:  G Damia; M D'Incalci
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

6.  Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.

Authors:  Jennifer L Dembinski; Shanna M Wilson; Erika L Spaeth; Matus Studeny; Claudia Zompetta; Ismael Samudio; Katherine Roby; Michael Andreeff; Frank C Marini
Journal:  Cytotherapy       Date:  2013-01       Impact factor: 5.414

7.  p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.

Authors:  D B Zamble; T Jacks; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

8.  Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy.

Authors:  C Compagnin; M Mognato; L Celotti; G Canti; G Palumbo; E Reddi
Journal:  Cell Prolif       Date:  2010-06       Impact factor: 6.831

9.  Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.

Authors:  Carmen Plasencia; Albert Abad; Eva Martinez-Balibrea; Miquel Taron
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

10.  NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.

Authors:  Eswar Shankar; Chandreyi Basu; Brett Adkins; Wolfram Siede; Alakananda Basu
Journal:  J Mol Signal       Date:  2010-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.